ANDA 76372, held by Teva Parenteral. Brimonidine Tartrate.
As of Nov 15, 2026, ANDA 76372 (Brimonidine Tartrate), held by Teva Parenteral, was first approved by FDA on Sep 10, 2004, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Brimonidine Tartrate0.2% ยท solution/drops;ophthalmic | Brimonidine Tartrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
